Bangkok Genomics Innovation PCL (BKK:BKGI) ROCE % : 10.32% (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bangkok Genomics Innovation PCL ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bangkok Genomics Innovation PCL's annualized ROCE % for the quarter that ended in Mar. 2024 was 10.32%.

Bangkok Genomics Innovation PCL ROCE % Historical Data

The historical data trend for Bangkok Genomics Innovation PCL's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bangkok Genomics Innovation PCL ROCE % Chart

Bangkok Genomics Innovation PCL Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

28.33

100.05

36.66

12.58

Bangkok Genomics Innovation PCL Quarterly Data
	Dec20	Dec21	Mar22	Dec22	Mar23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial			72.58	-	23.18	-	10.32

Bangkok Genomics Innovation PCL ROCE % Calculation

Bangkok Genomics Innovation PCL's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	33.584	/	( ( (300.577 - 23.941)	+	(293.021 - 35.563) )	/ 2 )
	=	33.584	/	( (276.636	+	257.458)	/ 2 )
	=	33.584	/	267.047
	=	12.58 %

Bangkok Genomics Innovation PCL's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	39.996	/	( ( (293.021 - 35.563)	+	(549.055 - 31.644) )	/ 2 )
	=	39.996	/	( ( 257.458	+	517.411 )	/ 2 )
	=	39.996	/	387.4345
	=	10.32 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Bangkok Genomics Innovation PCL (BKK:BKGI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bangkok Genomics Innovation PCL ROCE % Related Terms

Thank you for viewing the detailed overview of Bangkok Genomics Innovation PCL's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bangkok Genomics Innovation PCL (BKK:BKGI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Bangkok Genomics Innovation PCL (BKK:BKGI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3689 Rama 4 Road, Phra Khanong Subdistrict, Khlong Toei Subdistrict, Bangkok, THA, 10110

Website

https://www.bangkokgenomics.com

Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products).